Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Coivas vs MyFastRx

Coivas
Graded #198

Lower grade

vs+1.2000000000000028
MyFastRx
Graded #170

Higher grade

The verdict

MyFastRx takes it — 67.4/100 to 66.2/100, but only just.

MyFastRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MyFastRx is a cash-pay compounded-GLP-1 platform built around fast approval and discounted multi-month bundles. Coivas is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMyFastRx +5
70
75
Dose & formulationMyFastRx +8
64
72
Clinical oversightCoivas +18
84
66
Labs & monitoringCoivas +2
54
52
FulfillmentMyFastRx +5
78
83
Contract termsMyFastRx +21
20
41
Coivas · left barMyFastRx · right bar

The numbers

MetricCoivasMyFastRx
WeighScore66.2/10067.4/100
GradeCC
Scorecard rank#198#170
Semaglutide$149/mo (quarterly plan, compounded)$169/mo
Tirzepatide$229/mo (quarterly plan, compounded)$249/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Coivas

Graded #198 · C

Strengths

  • All-inclusive pricing: one price covers doctor consult, prescription, shipping and support
  • Compounded semaglutide from $149/mo and tirzepatide from $229/mo on the quarterly plan
  • Names its clinical provider (Arora Health & Aesthetics, LLC) and cites USP 797 / NABP-accredited pharmacies
  • Available in all 50 states; 24/7 support; HSA/FSA eligible; money-back guarantee
  • Most patients approved in under 2 hours; refund if no provider visit or prescription occurs

Where it loses points

  • Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
  • Lower quarterly headline price requires a 3-month commitment; monthly plan costs more ($179/$289)
  • Money-back guarantee has strict adherence/verification conditions and no partial/prorated refunds
  • No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only; binding NY arbitration
MyFastRx

Graded #170 · C

Strengths

  • Aggressive 12-month bundle pricing — $99/mo semaglutide, $149/mo tirzepatide
  • LegitScript certified
  • All doses priced the same — no cost escalation as you titrate up
  • First-month promo discount lowers the trial barrier

Where it loses points

  • States served not disclosed — only 'multiple states' / 'licensed U.S. providers'
  • Corporate address and medical director not published
  • Pharmacy partner not named — only 'state-licensed pharmacies'
  • Cash-pay only — no insurance billing
  • Bundle savings require a large upfront commitment (12 months billed at once)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard